Borneo Resource Investments, ticker BRNE. Borneo is a mining company that mines gold and develops producing gold mines in Indonesia. In this interview, Borneo CEO, Nils Ollquist tells viewers about the company, it’s operations in Indonesia, and future financial outlook.
If you want to learn more about Borneo Resource Investments you can visit the company’s website at http://www.borneore.com.
Interview with Dr. Pnina Fishman, CEO of Can-Fite Biopharma about the company’s new drug: CF101, which hopes to change the way Psoriasis is treated. To learn more visit: www.canfite.com
Glenn Bolduc, President and CEO of Implant Sciences, an up and coming technology leader in the homeland security space, talks about his company, products, and vision for the future. www.implantsciences.com Ticker: IMSC
Could Placental Cell Therapy be a Preemptive Approach to Protecting Women from Disabling Strokes?
Preeclampsia, a common pregnancy complication, has been around for centuries, it wasn’t until last year that 3 congresswomen designated May as Preeclampsia Awareness Month. This year, NJ Governor Chris Christie officiated the proclamation. The condition took an ominous turn, last month when the guidelines, published in the journal, Stroke, advise doctors to consider preeclampsia to be a stroke risk factor akin to smoking, high cholesterol, and obesity linking it to hypertension even years after the pregnancy. The alarming news has created new awareness of the condition and may open more dialogues about new treatments, which hasn’t occurred in 100 years. Could the answer to potentially reversing the hypertension and inflammation seen in preeclampsia be found in cells of a healthy placenta?
New promising evidence may lead scientists to answer that question. According to findings from an early preclinical study led by Brett Mitchell, PhD, an Associate Professor of Internal Medicine at the Cardiovascular Research Institute (CVRI) at Texas A&M University College of Medicine, there is evidence that administering placenta-derived cell therapy may help reverse the symptoms, including hypertension associated with preeclampsia in a matter of days after dosing with no harmful effects to mother or baby. Dr. Mitchell, who devoted many years of his research on hypertension with a particular focus on preeclampsia/gestational hypertension, delivered placenta-based cells called PLX (PLacental eXpanded) cells into mice who had preeclampsia. The PLX cells were created and patented by Israeli-based Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies.
The proteins released by the PLX cells help the body heal itself and release therapeutic proteins in response to signals from the patient’s body. Dr. Mitchell’s team found that PLX cells were indeed effective in treating preeclampsia in their animal models. The cells were proven to reverse the hypertension in the mice who eventually delivered healthy offspring. Armed with this data, Pluristem convened a Clinical Advisory Board comprised of some of the world’s expert thought leaders in preeclampsia. Pluristem plans US Phase I trials in 2014. The company recently announced that they are filing a FDA Orphan Drug status for their drug for the indication of preeclampsia.
In this interview Pluristem’s Dr. Karine Kleinhause sheds some light on the topic and Pluristem’s role in the potential treatment of preeclampsia. Dr. Karine Kleinhaus, M.D., MPH, is the Divisional Vice President, North America at Pluristem Therapeutics. Prior to r joining Pluristem Therapeutics, she was an assistant professor in the departments of psychiatry and obstetrics and gynecology at the NYU School of Medicine. At NYU, Dr. Kleinhaus conducted medical research funded under a multi-year NIH grant. She has published more than 25 papers in leading peer-reviewed journals such as the Annals of the New York Academy of Science, American Journal of Medical Genetics, and American Journal of Epidemiology. Prior to that Dr. Kleinhaus practiced obstetrics and completed two fellowships at Columbia University.
Dr. Kleinhaus received her medical degree from Tel Aviv University, earned a Master of Public Health from Columbia’s Mailman School of Public Health, and a bachelor’s degree, cum laude, from Princeton University.
Corporate Profile/ClearVISION Host Annamaria Chen sits down with Blackfish Director Gabriela Cowperthwaite to discuss her critically acclaimed film Blackfish. Gabriela talks about her inspiration, shocking discoveries, Pixar rumors, and her hopes for the future of SeaWorld.
About The Film:
Blackfish tells the story of Tilikum, a performing killer whale that killed several people while in captivity. Along the way, director-producer Gabriela Cowperthwaite compiles shocking footage and emotional interviews to explore the creature’s extraordinary nature, the species’ cruel treatment in captivity, the lives and losses of the trainers and the pressures brought to bear by the multi-billion dollar sea-park industry.
CEL-SCI CEO Geert Kersten talks about the future of the company and it’s lead investigational therapy Mutikine.
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. The lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial.